$1.850
-0.020 (-1.07%)Zum Schluss
CDIO-News
CDIO-Events
Cardio Diagnostics Partners with AHP to Cover Tests
Cardio Diagnostics Holdings announces that Atlas Healthcare Physicians, AHP, will cover Cardio Diagnostics' tests, Epi+Gen CHD and PrecisionCHD, for their members with prior authorization beginning May 2026.
Cardio Diagnostics Sets Final Payment Rate of $854 for Epi+Gen CHD and PrecisionCHD Tests
Cardio Diagnostics announced that the Centers for Medicare and Medicaid Services has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD and PrecisionCHD tests. This finalized rate represents an increase from the preliminary gapfill payment rates of $350 for Epi+Gen CHD and $684.76 for PrecisionCHD. Obtaining the final rate will be effective for claims with dates of service on or after January 1, 2026.
Cardio Diagnostics gets CMS gapfill payment rates for cardiovascular tests
Cardio Diagnostics announced that the Centers for Medicare and Medicaid Services, through the MolDX program, has issued preliminary gapfill payment rates of $350 for Epi+Gen CHD and $684.76 for PrecisionCHD. These preliminary rates, part of the 2025 gapfill pricing process, are expected to be finalized later this year and effective for claims on or after January 1, 2025. The company stated this is a critical step toward expanding access to its advanced cardiovascular testing for Medicare beneficiaries.
Cardio Diagnostics, AGEPHA Pharma in deal for heart disease study
Cardio Diagnostics Holdings and AGEPHA Pharma announced an agreement that will enable the validation of a precision-guided approach to treating inflammation-driven coronary heart disease. AGEPHA Pharma will supply its FDA-approved anti-inflammatory medication, LODOCO, for a Cardio Diagnostics-sponsored clinical study. The study will explore the use of Cardio Diagnostics' PrecisionCHD test to identify patients with inflammation-driven CHD and assess their response to LODOCO.
Cardio Diagnostics secures Japanese patent for set of biomarkers
Cardio Diagnostics announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company's intellectual property portfolio. The patent is exclusively licensed to Cardio Diagnostics from the University of Iowa Research Foundation and names Cardio Diagnostics' founders as inventors.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.